Acute Ocular Pain Drugs Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Prevalence, Incidence, Therapies, and Companies by DelveInsight

Companies involved in Acute Ocular Pain treatment include Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, among others
(New York, USA) DelveInsight's "Acute Ocular Pain Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Acute Ocular Pain, historical and forecasted epidemiology as well as the Acute Ocular Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The Acute Ocular Pain market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted AOP market size from 2020 to 2034, segmented by seven major markets. The Acute Ocular Pain Market Report also covers current Acute Ocular Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Acute Ocular Pain market.

To know in detail about the Acute Ocular Pain market outlook, drug uptake, treatment scenario and epidemiology trends, click here; Acute Ocular Pain Market Forecast [https://www.delveinsight.com/report-store/acute-ocular-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Acute Ocular Pain Market Report:

* The Acute Ocular Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In May 2024, Formosa Pharmaceuticals has obtained an exclusive licensing agreement with Tabuk Pharmaceuticals for the commercialization rights of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), in significant areas of the Middle East and North Africa (MENA). This advanced medication, which received FDA approval in March 2024, is designed to address inflammation and pain following ocular surgery.
* In 2023, conjunctivitis constituted about 34% of cases of acute ocular pain among prevalent eye disorders.
* In 2023, the United States had the highest prevalence of acute ocular pain cases among the 7MM.
* In 2023, within the EU4 and the UK, Germany reported the highest prevalence of acute ocular pain cases.
* At present, acute ocular pain is managed using NSAIDs, steroids, and other medications like antibiotics. These treatments are categorized into mono-therapies and combination therapies.
* In 2022, the United States reported 4,209,775 cases of Acute Ocular Pain (AOP), with an anticipated increase by 2034. Among the EU4 countries and the UK, Spain had the lowest incidence of AOP, with 539,419 cases reported in 2022.
* Recently approved medications such as DEXTENZA, INVELTYS, and LOTEMAX SM are specifically designed to address post-operative pain management following ocular surgery. Additionally, ongoing research is exploring other potential therapies for pain management, including APP13007, SURF-201, and SDN-037.
* Key Acute Ocular Pain Companies: Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others
* Key Acute Ocular Pain Therapies: APP13007, SURF-201, SDN-037, DEXTENZA (dexamethasone ophthalmic insert), INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121), BROMSITE (bromfenac ophthalmic solution), LOTEMAX SM (loteprednol etabonate ophthalmic gel), PROLENSA (bromfenac ophthalmic solution) 0.07%, and others
* The Acute Ocular Pain epidemiology based on gender analyzed that Acute Ocular Pain affects males and females equally
* The Acute Ocular Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Ocular Pain pipeline products will significantly revolutionize the Acute Ocular Pain market dynamics.

Acute Ocular Pain Overview

Acute ocular pain refers to a sudden onset of severe discomfort or pain in or around the eye, often indicating an underlying condition that requires prompt evaluation. It can stem from various causes, ranging from surface irritation to deeper, vision-threatening issues.

Common causes of acute ocular pain include corneal abrasions, foreign bodies, dry eye syndrome, or infections such as conjunctivitis or keratitis. More serious causes include acute glaucoma, uveitis, optic neuritis, or orbital cellulitis. Trauma, chemical exposure, and post-surgical complications can also trigger sudden eye pain. The pain may be accompanied by other symptoms like redness, sensitivity to light, tearing, visual disturbances, or discharge.

The severity and associated symptoms help differentiate between minor and serious causes. For example, acute angle-closure glaucoma often presents with pain, blurred vision, halos around lights, nausea, and vomiting, requiring emergency intervention to prevent permanent vision loss.

Diagnosis typically involves a thorough medical history, visual acuity tests, slit-lamp examination, and, in some cases, imaging or laboratory studies. Treatment varies depending on the cause and may include pain relief, antibiotics, anti-inflammatory agents, or surgical intervention. Early recognition and management of acute ocular pain are essential to preserve vision and prevent complications.

Get a Free sample for the Acute Ocular Pain Market Report: https://www.delveinsight.com/sample-request/acute-ocular-pain-market [https://www.delveinsight.com/sample-request/acute-ocular-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Acute Ocular Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Ocular Pain Epidemiology Segmentation:

The Acute Ocular Pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Acute Ocular Pain
* Prevalent Cases of Acute Ocular Pain by severity
* Gender-specific Prevalence of Acute Ocular Pain
* Diagnosed Cases of Episodic and Chronic Acute Ocular Pain

Download the report to understand which factors are driving Acute Ocular Pain epidemiology trends @ Acute Ocular Pain Epidemiology Forecast [https://www.delveinsight.com/report-store/acute-ocular-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Acute Ocular Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Ocular Pain market or expected to get launched during the study period. The analysis covers Acute Ocular Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Ocular Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Ocular Pain Therapies and Key Companies

* APP13007: Formosa Pharmaceuticals
* SURF-201: Surface Ophthalmics
* SDN-037: Sun Pharma Advanced Research Company Ltd (SPARC)
* DEXTENZA (dexamethasone ophthalmic insert): Ocular Therapeutix
* INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121): Kala Pharmaceuticals
* BROMSITE (bromfenac ophthalmic solution): Sun Pharmaceutical
* LOTEMAX SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb
* PROLENSA (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb

Acute Ocular Pain Market Strengths

* Strong guidelines and management has been described for differential diagnosis of acute ocular pain.
* Research and development is increasing the demand for better treatment options for acute ocular pain.

Request for sample report @ Acute Ocular Pain Clinical Trials [https://www.delveinsight.com/sample-request/acute-ocular-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Acute Ocular Pain Market opportunities

The current market does not have an approved therapy, particularly for the disease. Most of the available treatments target the disease or conditions causing acute ocular pain, thus creating a lucrative market opportunity.

As the lifestyle of people is changing day by day, people are moving towards unhygienic lifestyle which has increased the chances of bacterial and fungal infections, leading to more and more eye infections.

Scope of the Acute Ocular Pain Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Acute Ocular Pain Companies: Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others
* Key Acute Ocular Pain Therapies: APP13007, SURF-201, SDN-037, DEXTENZA (dexamethasone ophthalmic insert), INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121), BROMSITE (bromfenac ophthalmic solution), LOTEMAX SM (loteprednol etabonate ophthalmic gel), PROLENSA (bromfenac ophthalmic solution) 0.07%, and others
* Acute Ocular Pain Therapeutic Assessment: Acute Ocular Pain current marketed and Acute Ocular Pain emerging therapies
* Acute Ocular Pain Market Dynamics: Acute Ocular Pain market drivers and Acute Ocular Pain market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Acute Ocular Pain Unmet Needs, KOL's views, Analyst's views, Acute Ocular Pain Market Access and Reimbursement

To know more about Acute Ocular Pain companies working in the treatment market, visit @ Acute Ocular Pain Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/acute-ocular-pain-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Acute Ocular Pain Market Report Introduction

2. Executive Summary for Acute Ocular Pain

3. SWOT analysis of Acute Ocular Pain

4. Acute Ocular Pain Patient Share (%) Overview at a Glance

5. Acute Ocular Pain Market Overview at a Glance

6. Acute Ocular Pain Disease Background and Overview

7. Acute Ocular Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Ocular Pain

9. Acute Ocular Pain Current Treatment and Medical Practices

10. Acute Ocular Pain Unmet Needs

11. Acute Ocular Pain Emerging Therapies

12. Acute Ocular Pain Market Outlook

13. Country-Wise Acute Ocular Pain Market Analysis (2020-2034)

14. Acute Ocular Pain Market Access and Reimbursement of Therapies

15. Acute Ocular Pain Market Drivers

16. Acute Ocular Pain Market Barriers

17. Acute Ocular Pain Appendix

18. Acute Ocular Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-ocular-pain-drugs-market-2034-ema-pdma-fda-approvals-medication-clinical-trials-prevalence-incidence-therapies-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.